Octapharma USA, Inc., Vice President, US Medical Affairs Hematology, Immunology and Critical Care.

Huub’s extensive medical, clinical, scientific and executive experience provides world-class expertise in immunotherapy treatments for CPAE Disorders like PANS/PANDAS.  As Vice President of Octapharma USA Inc, Huub contributes to our Board information on state-of-the art product development of the highly beneficial biopharmaceutical plasma therapies being used for treatment.  Octapharma, the parent company, is the world’s largest privately held plasma therapeutics company with products sold in North America, Europe, Russia, Brazil, Australia, the Middle East and emerging economies.

His executive position at Octapharma USA includes the development and management of medical affairs teams for nine products addressing Hematology, Immunology and Critical Care.  Huub’s current and past career professions help lead PACE with our educational, governmental, medical and clinical strategies for IVIG treatments at CPAE clinics and centers nationwide.  His scientific and medical knowledge in post infectious immune deficiencies has guided PACE’s research collaboration between clinical staff and leading universities.  Huub has a lengthy background in reviewing medical and clinical effectiveness of product development from his employment at Baxter Healthcare and Johnson and Johnson.  Huub has authored and co-authored scores of scientific articles published in various medical journals.